1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Cyclic nucleotide phosphodiesterases.

      The Journal of Allergy and Clinical Immunology

      Adjuvants, Immunologic, pharmacology, therapeutic use, Antigen-Presenting Cells, drug effects, enzymology, Clinical Trials as Topic, Cyclic AMP, physiology, Cyclic GMP, Endothelium, Granulocytes, Humans, Lymphocytes, Mast Cells, Models, Biological, Phosphodiesterase Inhibitors, Phosphoric Diester Hydrolases, chemistry, classification

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cyclic nucleotide second messengers (cAMP and cGMP) play a central role in signal transduction and regulation of physiologic responses. Their intracellular levels are controlled by the complex superfamily of cyclic nucleotide phosphodiesterase (PDE) enzymes. Continuing advances in our understanding of the molecular pharmacology of these enzymes has led to the development of selective inhibitors as therapeutic agents for disease states ranging from cancer and heart failure to depression and sexual dysfunction. Several PDE types have been identified as therapeutic targets for immune/inflammatory diseases. This article briefly reviews the available in vitro, preclinical, and clinical data supporting the potential for selective PDE inhibitors as immunomodulatory agents.

          Related collections

          Author and article information

          Journal
          11692087
          10.1067/mai.2001.119555

          Comments

          Comment on this article